Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator

Paul R. Eisenberg, Burton E. Sobel, Allan S Jaffe

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Increases in thrombin activity in patients given fibrinolytic agents for acute myocardial infarction have been shown to be important in limiting the ultimate success of coronary thrombolysis. The present study was designed to determine whether increases in thrombin activity reflect, in part, activation of prothrombin accompanying thrombolysis. Plasma concentrations of prothrombin fragment 1.2, a polypeptide released when prothrombin is activated by factor Xa, were measured in 22 patients with acute myocardial infarction before and after treatment with 100 mg of recombinant tissue-type plasminogen activator (rt-PA). Concentrations of prothrombin fragment 1.2 increased from 0.83 ± 1.1 nM (mean ± SD) before rt-PA infusion to 1.5 ± 1.5 nM 2 h after initiation of the infusion (p < 0.05). After a 5,000-U intravenous dose of heparin given at the end of the infusion of rt-PA, concentrations of prothrombin fragment 1.2 decreased from 1.8 ± 1.5 to 1.1 ± 0.9 nM (n = 20, p < 0.05), although values were still increased compared with concentrations before rt-PA. These results indicate that thrombin activity increases in patients given rt-PA at least in part because of activation of the coagulation system leading to activation of prothrombin. Thus, inhibition of the reactions involving coagulant proteins that lead to activation of prothrombin may be of value as conjunctive treatment to potentiate the efficacy of pharmacologic thrombolysis.

Original languageEnglish (US)
Pages (from-to)1065-1069
Number of pages5
JournalJournal of the American College of Cardiology
Volume19
Issue number5
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Prothrombin
Tissue Plasminogen Activator
Thrombin
Myocardial Infarction
Coagulants
Factor Xa
Fibrinolytic Agents
Heparin
Peptides
Therapeutics
prothrombin fragment 1.2
Proteins

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. / Eisenberg, Paul R.; Sobel, Burton E.; Jaffe, Allan S.

In: Journal of the American College of Cardiology, Vol. 19, No. 5, 1992, p. 1065-1069.

Research output: Contribution to journalArticle

@article{5e026a4295ec493b8e2fd20dd4abd6ce,
title = "Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator",
abstract = "Increases in thrombin activity in patients given fibrinolytic agents for acute myocardial infarction have been shown to be important in limiting the ultimate success of coronary thrombolysis. The present study was designed to determine whether increases in thrombin activity reflect, in part, activation of prothrombin accompanying thrombolysis. Plasma concentrations of prothrombin fragment 1.2, a polypeptide released when prothrombin is activated by factor Xa, were measured in 22 patients with acute myocardial infarction before and after treatment with 100 mg of recombinant tissue-type plasminogen activator (rt-PA). Concentrations of prothrombin fragment 1.2 increased from 0.83 ± 1.1 nM (mean ± SD) before rt-PA infusion to 1.5 ± 1.5 nM 2 h after initiation of the infusion (p < 0.05). After a 5,000-U intravenous dose of heparin given at the end of the infusion of rt-PA, concentrations of prothrombin fragment 1.2 decreased from 1.8 ± 1.5 to 1.1 ± 0.9 nM (n = 20, p < 0.05), although values were still increased compared with concentrations before rt-PA. These results indicate that thrombin activity increases in patients given rt-PA at least in part because of activation of the coagulation system leading to activation of prothrombin. Thus, inhibition of the reactions involving coagulant proteins that lead to activation of prothrombin may be of value as conjunctive treatment to potentiate the efficacy of pharmacologic thrombolysis.",
author = "Eisenberg, {Paul R.} and Sobel, {Burton E.} and Jaffe, {Allan S}",
year = "1992",
doi = "10.1016/0735-1097(92)90296-Y",
language = "English (US)",
volume = "19",
pages = "1065--1069",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator

AU - Eisenberg, Paul R.

AU - Sobel, Burton E.

AU - Jaffe, Allan S

PY - 1992

Y1 - 1992

N2 - Increases in thrombin activity in patients given fibrinolytic agents for acute myocardial infarction have been shown to be important in limiting the ultimate success of coronary thrombolysis. The present study was designed to determine whether increases in thrombin activity reflect, in part, activation of prothrombin accompanying thrombolysis. Plasma concentrations of prothrombin fragment 1.2, a polypeptide released when prothrombin is activated by factor Xa, were measured in 22 patients with acute myocardial infarction before and after treatment with 100 mg of recombinant tissue-type plasminogen activator (rt-PA). Concentrations of prothrombin fragment 1.2 increased from 0.83 ± 1.1 nM (mean ± SD) before rt-PA infusion to 1.5 ± 1.5 nM 2 h after initiation of the infusion (p < 0.05). After a 5,000-U intravenous dose of heparin given at the end of the infusion of rt-PA, concentrations of prothrombin fragment 1.2 decreased from 1.8 ± 1.5 to 1.1 ± 0.9 nM (n = 20, p < 0.05), although values were still increased compared with concentrations before rt-PA. These results indicate that thrombin activity increases in patients given rt-PA at least in part because of activation of the coagulation system leading to activation of prothrombin. Thus, inhibition of the reactions involving coagulant proteins that lead to activation of prothrombin may be of value as conjunctive treatment to potentiate the efficacy of pharmacologic thrombolysis.

AB - Increases in thrombin activity in patients given fibrinolytic agents for acute myocardial infarction have been shown to be important in limiting the ultimate success of coronary thrombolysis. The present study was designed to determine whether increases in thrombin activity reflect, in part, activation of prothrombin accompanying thrombolysis. Plasma concentrations of prothrombin fragment 1.2, a polypeptide released when prothrombin is activated by factor Xa, were measured in 22 patients with acute myocardial infarction before and after treatment with 100 mg of recombinant tissue-type plasminogen activator (rt-PA). Concentrations of prothrombin fragment 1.2 increased from 0.83 ± 1.1 nM (mean ± SD) before rt-PA infusion to 1.5 ± 1.5 nM 2 h after initiation of the infusion (p < 0.05). After a 5,000-U intravenous dose of heparin given at the end of the infusion of rt-PA, concentrations of prothrombin fragment 1.2 decreased from 1.8 ± 1.5 to 1.1 ± 0.9 nM (n = 20, p < 0.05), although values were still increased compared with concentrations before rt-PA. These results indicate that thrombin activity increases in patients given rt-PA at least in part because of activation of the coagulation system leading to activation of prothrombin. Thus, inhibition of the reactions involving coagulant proteins that lead to activation of prothrombin may be of value as conjunctive treatment to potentiate the efficacy of pharmacologic thrombolysis.

UR - http://www.scopus.com/inward/record.url?scp=0026510405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026510405&partnerID=8YFLogxK

U2 - 10.1016/0735-1097(92)90296-Y

DO - 10.1016/0735-1097(92)90296-Y

M3 - Article

C2 - 1552097

AN - SCOPUS:0026510405

VL - 19

SP - 1065

EP - 1069

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 5

ER -